Adamis Pharmaceuticals (NASDAQ: ADMP) was in the news earlier this week after the company provided an update with regards to one of its products.
In this regard, it is also necessary to point out that the Adamis stock has performed poorly over the past two months. During that period, the stock has declined by 50%. On Monday, the company provided an update with regards to the New Drug Application that it had submitted in relation to its high dosage naloxone injection ZIMHI.
Adamis announced that it had a meeting with the United States Food and Drug Administration in which the comments in relation to the additional information provided by the company were reviewed. The company had provided the information in response to the Complete Response Letter from the FDA earlier. Adamis revealed that the meeting with the FDA was productive. Now it remains to be seen if the latest announcement from the company can provide any boost to its stock or not.